Quest Diagnostics Incorporated
DGXUSQuest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.
- Sector
- Healthcare Services
- Sub-sector
- Diagnostics & Clinical Services
- Listing
- DGX
- Country
- US
Annual financials & analyst forecasts
| $M | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | CY2026E | CY2027E |
|---|---|---|---|---|---|---|---|
| Revenue YoY | — | -8% | -6% | 7% | 12% | 9% | 5% |
| Revenue | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B | $12.00B | $12.56B |
| Gross Profit | $4.21B | $3.43B | $3.06B | $3.24B | $3.67B | — | — |
| Gross Profit Margin | 39.0% | 34.7% | 33.0% | 32.9% | 33.2% | — | — |
| EBITDA | $3.16B | $1.82B | $1.73B | $1.90B | $2.18B | $2.53B | $2.65B |
| EBITDA Margin | 29.3% | 18.4% | 18.7% | 19.2% | 19.7% | 21.1% | 21.1% |
| EBIT | $2.38B | $1.43B | $1.26B | $1.35B | $1.56B | $1.98B | $2.07B |
| Net Income | $1.99B | $942M | $854M | $871M | $992M | $1.25B | $1.34B |
| Free Cash Flow | $1.83B | $1.31B | $864M | $909M | $1.36B | — | — |
| FCF Margin | 17.0% | 13.3% | 9.3% | 9.2% | 12.3% | — | — |
| Short-Term Debt | $153M | $155M | $456M | $775M | $678M | — | — |
| Long-Term Debt | $4.01B | $3.98B | $4.41B | $5.60B | $5.70B | — | — |
| Cash & Cash Equivalents | $872M | $315M | $686M | $549M | $420M | — | — |
| Net Debt | $3.29B | $3.82B | $4.18B | $5.83B | $5.96B | — | — |
| Net Debt / EBITDA | 1.0x | 2.1x | 2.4x | 3.1x | 2.7x | — | — |
| Rule of 40 | — | 4.9% | 3.0% | 15.9% | 24.1% | — | — |